A5080071210- Pharmacogenetics and Drug Metabolism
- Receptor Mechanisms and Signaling
- Drug Transport and Resistance Mechanisms
- Protein Degradation and Inhibitors
- Software Testing and Debugging Techniques
- Protein purification and stability
- Computational Drug Discovery Methods
- Toxic Organic Pollutants Impact
Janssen (United States)
2022-2023
Novartis (United States)
2023
AstraZeneca (United Kingdom)
2023
Roche (Switzerland)
2023
Amgen (United States)
2023
Takeda (United States)
2023
Merck (Germany)
2023
AbbVie (United States)
2023
GlaxoSmithKline (United Kingdom)
2023
Neurocrine Biosciences (United States)
2022
[4-(4-Methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-yl)pyrimidine-2-amine] (JNJ-2482272), under investigation as an anti-inflammatory agent, was orally administered to rats once daily at 60 mg/kg for 6 consecutive days. Despite high plasma exposure after single administration (Cmax of 7.1 μM), JNJ-2482272 had concentrations beneath the lower limit quantification (3 ng/ml) days dosing. To determine if is autoinducer in rats, plated rat hepatocytes were treated with 2 The major hydroxylated...